Lunai Bioworks (LNAI) Return on Capital Employed (2012 - 2026)
Lunai Bioworks (LNAI) posted quarterly Return on Capital Employed of 1211.78% for Q1 2026, up 130415.0% year-over-year from N/an in Q1 2025, and up 17.32% quarter-over-quarter from 1032.85% in Q4 2025.
Lunai Bioworks (LNAI) Return on Capital Employed (2012 - 2026) Analysis & Trends
Lunai Bioworks' Return on Capital Employed history runs 15 years deep, the most recent figure standing at 1211.78% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 130415.0% year-over-year to 1211.78%; the TTM figure through Mar 2026 stood at 1211.78% (up 130415.0% YoY), while the FY2025 annual figure was 334.31%, down 23278.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 1211.78%, up from 1032.85% in the prior quarter.
- The five-year high for Return on Capital Employed was 1211.78% in Q1 2026, with the low at 558.7% in Q2 2025.
- The 5-year median for Return on Capital Employed is 91.19% (2023), against an average of 88.71%.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed tumbled 50051 bps in 2025, then surged 130415 bps in 2026.
- Lunai Bioworks' Return on Capital Employed stood at 161.7% in 2022, then jumped by 44 bps to 91.19% in 2023, then plunged by 58 bps to 143.64% in 2024, then jumped by 819 bps to 1032.85% in 2025, then climbed by 17 bps to 1211.78% in 2026.
- Business Quant data shows LNAI's Return on Capital Employed at 1211.78% in Q1 2026, 1032.85% in Q4 2025, and 1145.7% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.96 Bn | 132.11 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.20 Bn | 55.06 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.19 Bn | 37.09 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.43 Bn | 28.12 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 7.88% |
| 10 | Lunai Bioworks | 7.12 Mn | 3.97 Mn | 20,942.00 | 1,211.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,211.78% |
| Dec 31, 2025 | 1,032.85% |
| Sep 30, 2025 | 1,145.70% |
| Jun 30, 2025 | -558.70% |
| Mar 31, 2025 | -92.37% |
| Dec 31, 2024 | -143.64% |
| Sep 30, 2024 | -105.57% |
| Jun 30, 2024 | -58.19% |
| Mar 31, 2024 | -90.01% |
| Dec 31, 2023 | -91.19% |
| Sep 30, 2023 | -84.14% |
| Jun 30, 2023 | -67.06% |
| Mar 31, 2023 | -168.07% |
| Dec 31, 2022 | -161.70% |
| Sep 30, 2022 | -150.95% |
| Jun 30, 2022 | -92.19% |
| Mar 31, 2022 | -18.41% |
| Dec 31, 2021 | -17.52% |
| Sep 30, 2021 | -15.11% |
| Jun 30, 2021 | -13.02% |